Structure Therapeutics Future Growth
Future criteria checks 2/6
Structure Therapeutics's earnings are forecast to decline at 22% per annum while its annual revenue is expected to grow at 49.7% per year. EPS is expected to grow by 2.9% per annum.
Key information
-22.0%
Earnings growth rate
2.9%
EPS growth rate
Pharmaceuticals earnings growth | 23.5% |
Revenue growth rate | 49.7% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 10 May 2024 |
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -229 | -282 | -185 | 6 |
12/31/2025 | 25 | -152 | -201 | -176 | 8 |
12/31/2024 | N/A | -126 | -199 | -114 | 8 |
3/31/2024 | N/A | -98 | -96 | -93 | N/A |
12/31/2023 | N/A | -90 | -82 | -79 | N/A |
9/30/2023 | N/A | -77 | -71 | -70 | N/A |
6/30/2023 | N/A | -66 | -60 | -60 | N/A |
3/31/2023 | N/A | -58 | -53 | -53 | N/A |
12/31/2022 | N/A | -53 | -46 | -46 | N/A |
9/30/2022 | N/A | -56 | -45 | -45 | N/A |
12/31/2021 | N/A | -44 | -33 | -32 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GPCR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GPCR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GPCR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GPCR's revenue (49.7% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: GPCR's revenue (49.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GPCR's Return on Equity is forecast to be high in 3 years time